Log in to search using one of your social media accounts:

 

Medical News Today: Lowering cholesterol improves cancer-fighting immunotherapy
A recent study demonstrates that a certain type of cancer immunotherapy might be enhanced simply by reducing cholesterol levels in cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 19, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Trial'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer Trial'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer
Thoracic oncologists Drs Jack West and Hossein Borghaei discuss critical questions in the treatment of low-expressing or PD-L1-negative non-small cell lung cancer patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Life-Saving Cancer Meds Tied to Vision Loss
New research reports on three cases of a potentially vision-threatening eye condition called uveal effusion that patients developed after taking cancer immunotherapy. (Source: WebMD Health)
Source: WebMD Health - May 18, 2018 Category: Consumer Health News Source Type: news

KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC
While KEYNOTE-189 answered many questions about immuno-oncology for NSCLC, Drs West and Borghaei look forward to results of KEYNOTE-042 for even more answers.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Medical News Today: Why is lung cancer so difficult to treat?
Immunotherapies often fail to halt lung cancer's progression. A new study attempts to understand why this is and design a new way to attack it. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 17, 2018 Category: Consumer Health News Tags: Lung Cancer Source Type: news

ONCOS-102 Mesothelioma Trial Moves Forward
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - May 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Men May Gain More From Cancer Immunotherapy
Researchers found that all the patients fared better on immunotherapy treatment than they would have on another treatment (or no treatment at all). But following treatment, male cancer patients saw their survival extended by twice as much as female patients. (Source: WebMD Health)
Source: WebMD Health - May 17, 2018 Category: Consumer Health News Source Type: news

Men May Gain More From Cancer Immunotherapy
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 17, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news

Men May Gain More From Cancer Immunotherapy
THURSDAY, May 17, 2018 -- Male cancer patients seem to fare significantly better following immunotherapy treatment than female patients, new research indicates. " Both sex and gender can potentially affect the strength of the body's immune... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 17, 2018 Category: General Medicine Source Type: news

Medical News Today: Cancer: Does sex affect the outcome of immunotherapy?
Therapies that help the immune system to fight tumors have gained popularity over time. But are we leaving a key element — sex — out of clinical trials? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 17, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Immuno-PET tracer offers hope for early cancer treatment
Researchers are developing a PET radiotracer designed to adhere to and illuminate...Read more on AuntMinnie.comRelated Reading: MRI holds promise for immunotherapy but needs more research Novel PET tracer could identify bacterial infections Immuno-PET radiotracers may aid cancer treatment Novel PET tracer aids recurrent prostate cancer patients Radiation, immunotherapy form best team against melanoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 17, 2018 Category: Radiology Source Type: news

Men May Gain More From Cancer Immunotherapy
Title: Men May Gain More From Cancer ImmunotherapyCategory: Health NewsCreated: 5/17/2018 12:00:00 AMLast Editorial Review: 5/17/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 17, 2018 Category: Cancer & Oncology Source Type: news

A New Era of Proactive Melanoma Therapy: Hit Hard, Hit Early A New Era of Proactive Melanoma Therapy: Hit Hard, Hit Early
This editorial discusses the ramifications of three recent, pivotal melanoma trials of targeted and immunotherapies.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Men May Gain More From Cancer Immunotherapy
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - May 17, 2018 Category: Cancer & Oncology Source Type: news

Better Responses to Immunotherapy in Men Better Responses to Immunotherapy in Men
When patients with advanced solid tumors are treated with immune checkpoint inhibitors, only men get double the survival benefits seen with standard cancer therapies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Men Do Better than Women on Cancer Immunotherapies
(MedPage Today) -- Overall survival improvement twice as great, meta-analysis finds (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 16, 2018 Category: Primary Care Source Type: news

Roche immunotherapy combination increases lung cancer survival - study
(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck's Keytruda boosts response in hard-to-treat lung cancer
(Reuters) - The combination of Merck& Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Duke Team Addresses Barriers to Oral Chemo
A streamlined nursing protocol reduced delays related to treatment with oral formulations of chemotherapy and immunotherapy, and increased patient satisfaction. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: Lori Smith, BSN, MSN, CRNP Tags: News Conferences/ONS Source Type: news

Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients? Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients?
Thoracic oncologists Drs Jack West and Hossein Borghaei talk about when to add chemotherapy to immunotherapy in high PD-L1-expressing non-small cell lung cancer patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Hay fever symptoms - is this the cure for pollen allergy? How to get immunotherapy jabs
HAY fever symptoms include sneezing, headaches, runny noses and itchy throats. If hay fever tablets or other treatments don ’t work for you, you could be eligible for immunotherapy. What is the injection treatment, and could it cure your allergy? (Source: Daily Express - Health)
Source: Daily Express - Health - May 16, 2018 Category: Consumer Health News Source Type: news

TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
Welcomes Renowned Thought Leaders Dr. Malcolm Brenner, Dr. Helen Heslop, and Dr. Cliona Rooney JACKSONVILLE, Fla., May 16, 2018 -- (Healthcare Sales & Marketing Network) -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today ... Biopharmaceuticals, Oncology, Personnel TapImmune, Marker Therapeutics, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 16, 2018 Category: Pharmaceuticals Source Type: news

Reducing cholesterol could enhance T-cell cancer immunotherapy
(Cleveland Clinic) Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer. The team, led by Qing Yi, M.D., Ph.D., of Cleveland Clinic Lerner Research Institute studied T-cell transfer, which has shown great success in recent years. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

The Lancet Oncology: Patients' sex may impact efficacy of immunotherapy in cancer treatment
(The Lancet) A patient's sex might impact on the efficacy of immunotherapy in cancer treatment, according to a new meta-analysis of 20 randomised trials in over 11000 patients with advanced cancer published in The Lancet Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news

Florida and Minnesota immunotherapy cos. to merge, move HQ to Houston
TapImmune Inc. (Nasdaq: TPIV), a Jacksonville, Florida-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston, due to a strategic alliance with Baylor College of Medicine. TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. The combined company will… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 15, 2018 Category: Biotechnology Authors: Will Robinson Source Type: news

Merger takes Jacksonville immunotherapy company to Houston
TapImmune Inc. (Nasdaq: TPIV), the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston. TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. “I believe that the new therapies we are acquiring with Marker in this transaction represent… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 15, 2018 Category: Health Management Authors: Will Robinson Source Type: news

Merger takes Jacksonville immunotherapy company to Houston
TapImmune Inc. (Nasdaq: TPIV), the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies. The newly formed company will be based in Houston, due to a strategic alliance with the Baylor College of Medicine. TapImmune and Marker will each own half of the company, though the deal is still subject to the approval of TapImmune's stockholders. Marker is privately held. The combined company will… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 15, 2018 Category: Biotechnology Authors: Will Robinson Source Type: news

Broad Institute Spinout Aims To Bring Precision Medicine To Autoimmune Disease
Celsius Therapeutics will use techniques for constructing detailed profiles of individual cells to develop drugs for autoimmune diseases and cancer immunotherapies. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 15, 2018 Category: Pharmaceuticals Authors: Ellie Kincaid, Forbes Staff Source Type: news

Immunicom's Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer
SAN DIEGO, May 14, 2018 -- (Healthcare Sales & Marketing Network) -- Immunicom, Inc., a medical technology company developing revolutionary non-pharmaceutical approaches for treating cancer and autoimmune diseases, has received Breakthrough Device designa... Devices, Oncology, FDA Immunicom, Immunopheresis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 14, 2018 Category: Pharmaceuticals Source Type: news

Better equipped in the fight against lung cancer
(University of Erlangen-Nuremberg) Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women. However, immunotherapies are successful in only 20 percent of cases. Researchers at Friedrich-Alexander-Universit ä t Erlangen-N ü rnberg (FAU) have now discovered a special mechanism that regulates tumour growth in lung cancer. This opens up new possibilities in the treatment of lung cancer patients. The results were published in the journal Oncoimmunology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2018 Category: Cancer & Oncology Source Type: news

Duane A. Mitchell, M.D., Ph.D., World-Renowned Immunotherapy Expert to...
Director of the University of Florida Brain Tumor Immunotherapy Program will share his unique perspective on the role of immunotherapy in treating brain cancer(PRWeb May 14, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15484641.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 14, 2018 Category: Pharmaceuticals Source Type: news

University of Colorado Cancer Center Study Hints at New Target to...
Eya3 inhibition could be an attractive strategy to increase effectiveness of anti-PD-L1 immunotherapies against triple-negative breast cancer.(PRWeb May 14, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15477653.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 14, 2018 Category: Pharmaceuticals Source Type: news

Setback to Roche Hopes for Tecentriq as Fails Key Cancer Trial Setback to Roche Hopes for Tecentriq as Fails Key Cancer Trial
Roche's hopes of its Tecentriq (atezolizumab) immunotherapy catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

CRC Polyps May Allow for Immune Checkpoint Inhibitors in Premalignant Lesions
Colorectal carcinomas in LS patients appear in background of mismatch repair (MMR) deficiency, show a unique immune profile, and response to immunotherapy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

Biotech buyout means happy returns for Kleiner Perkins
A small biotech's $1.6 billion buyout by Eli Lilly and Co. would create big Bay Area venture capital winners — including a 50x return for Kleiner Perkins Caufield& Byers — and could turn the cancer immunotherapy investing space white hot. Lilly (NYSE: LLY) will buy ARMO BioSciences Inc. (NASDAQ: ARMO) for $50 a share in an all-cash deal that is nearly triple the price of the Redwood City company's shares when it went public in January. That means big winners amo ng early investors who saw the… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 11, 2018 Category: Health Management Authors: Ron Leuty Source Type: news

Photopheresis: A cancer treatment that goes beyond skin deep
Shedding light on new uses for Photopheresis, a cellular immunotherapy developed by Yale Medicine ’s chair of dermatology, Dr. Richard Edelson. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 11, 2018 Category: Universities & Medical Training Source Type: news

Is This New Immunotherapy Biomarker Really'Ready for Primetime'? Is This New Immunotherapy Biomarker Really'Ready for Primetime'?
Drs West and Borghaei discuss the current state of tumor mutational burden as a potential biomarker for lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs
A small Peninsula biotech's $1.6 billion buyout by Eli Lilly and Co. would create big Bay Area venture capital winners — including a 50x return for Kleiner Perkins Caufield& Byers — and could turn the cancer immunotherapy investing space white hot. Lilly (NYSE: LLY) will buy ARMO BioSciences Inc. (NASDAQ: ARMO) for $50 a share in an all-cash deal that is nearly triple the price of the Redwood City company's shares when it went public in January. That means big winners amo ng early investors… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 11, 2018 Category: American Health Authors: Ron Leuty Source Type: news

Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs
A small Peninsula biotech's $1.6 billion buyout by Eli Lilly and Co. would create big Bay Area venture capital winners — including a 50x return for Kleiner Perkins Caufield& Byers — and could turn the cancer immunotherapy investing space white hot. Lilly (NYSE: LLY) will buy ARMO BioSciences Inc. (NASDAQ: ARMO) for $50 a share in an all-cash deal that is nearly triple the price of the Redwood City company's shares when it went public in January. That means big winners amo ng early investors… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 11, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Diversity of gut microbiome linked to artery hardening
Link may explain cardiovascular risk in people without the usual risk factors, researchers say Related items fromOnMedica Gut bacteria may play role in neurodegenerative diseases Gut microbes help immunotherapy treatment Electronic ‘pill’ may revolutionise gut diagnoses Atrial fibrillation risk lower with regular nut consumption (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 11, 2018 Category: UK Health Source Type: news

Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs
A small Peninsula biotech's $1.6 billion buyout by Eli Lilly and Co. would create big Bay Area venture capital winners — including a 50x return for Kleiner Perkins Caufield& Byers — and could turn the cancer immunotherapy investing space white hot. Lilly (NYSE: LLY) will buy ARMO BioSciences Inc. (NASDAQ: ARMO) for $50 a share in an all-cash deal that is nearly triple the price of the Redwood City company's shares when it went public in January. That means big winners amo ng early investors… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 10, 2018 Category: Health Management Authors: Ron Leuty Source Type: news

Uveal Effusion Reported After Initiation of Anti-PD-1, -PD-L1
THURSDAY, May 10, 2018 -- Patients receiving immunotherapy with antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies may develop uveal effusion, according to a report published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 10, 2018 Category: Pharmaceuticals Source Type: news

How this biotech nearly tripled its IPO price with a buyout in less than 4 months
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal. Lilly's $50-per-share buyout is nearly three times ARMO's (NASDAQ: ARMO) $17-per-share initial public offering price, offering a relatively quick return for investors, including venture capital firms Kleiner Perkins Caufield& Byers and OrbiMed Advisors, whose public shares still were under customary IPO lockups. … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 10, 2018 Category: American Health Authors: Ron Leuty Source Type: news

New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer drugs known as checkpoint inhibitors received treatment within months of FDA approval, according to a new study. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 10, 2018 Category: Universities & Medical Training Source Type: news

Setback to Roche hopes for Tecentriq as fails key cancer trial
ZURICH (Reuters) - Roche's hopes of its Tecentriq immunotherapy catching up rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial. (Source: Reuters: Health)
Source: Reuters: Health - May 10, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

New cancer immunotherapy drugs rapidly reach patients after approval
(Yale University) The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

A new cancer immunotherapy suffers a setback
(Source: ScienceNOW)
Source: ScienceNOW - May 10, 2018 Category: Science Authors: Garber, K. Tags: Cell Biology, Medicine, Diseases In Depth Source Type: news

Society for Immunotherapy of Cancer (SITC)-Led Study Demonstrating...
An international consortium led by the Society for Immunotherapy of Cancer (SITC) has published the results of a ground-breaking study that demonstrates the immune system’s important role in colon...(PRWeb May 10, 2018)Read the full story at http://www.prweb.com/releases/2018/05/prweb15479857.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 10, 2018 Category: Pharmaceuticals Source Type: news

New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. (Source: World Pharma News)
Source: World Pharma News - May 9, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

How KU Cancer Center landed trial for Novartis' cancer gene therapy
Dr. Roy Jensen, director of the University of Kansas Cancer Center, explains how the hospital's ability to attract immunotherapy trials traced back to a decision 11 years ago. The subsequent buildout of its clinical research infrastructure gave it access to Novartis' trial of Kymriah. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 8, 2018 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news